
14.2.2 Secondary endpoints

14.2.2.1-2 Overall survival

Figure 14.2.2.1: Overall survival from eligibility - Full Analysis Population



ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic stem cell transplantation.

Table 14.2.2.2.1: Comparison of Overall survival at 3 years after start of investigational treatment between SCT and ContRuxo - Full Analysis Population

Timepoint	Treatment arm	Survival Function Estimate, S(t)	Standard Error	Absolute difference in S(t)	95% Lower confidence interval for absolute difference	95% Upper confidence interval for absolute difference	Z-value	P-value
3 years	ContRuxo	0.833	0.108	0.003	-0.229	0.236	0.026	0.979
	SCT	0.836	0.050					

ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic stem cell transplantation. 3 years defined as 3 years + 92 days after the date of inclusion to allow for Ruxolitinib induction period.
All numerical values are rounded to 3 decimal places. Standard error calculated using Greenwood's formula.
Reference- Cantor AB. Projecting the standard error of the Kaplan-Meier estimator. Stat Med. 2001 Jul 30;20(14):2091-7. doi: 10.1002/sim.856. PMID: 11439423.

Page 1 of 1

Table 14.2.2.2.2: Median follow up time

Population	Treatment arm	N	Median FU time in days	95% Lower confidence interval	95% Upper confidence interval	Range of FU time in days
FAP	ContRuxo	14	1176	1170	-	169 - 1253
	SCT	57	1231	1212	1253	173 - 1439
EP	ContRuxo	16	1176	1097	1245	169 - 1253
	SCT	64	1219	1193	1245	173 - 1439

ContRuxo: Ruxolitinib continuous therapy. EP: Entered population. FAP: Full analysis population. FU: follow-up. SCT: Allogeneic stem cell transplantation.

Page 1 of 1